Third Harmonic Bio (THRD) Stock Analysis

What Third Harmonic Bio does

Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT. This compound is being advanced to address chronic urticaria—a skin ailment characterized by painful, itchy red welts (hives) stemming from mast cell overactivity—and is also being explored for its potential in respiratory and digestive tract disorders. Previously known as Project IGE, Inc., the company adopted its current name, Third Harmonic Bio, Inc., in June of 2019. Established in 2019, its corporate headquarters are situated in Cambridge, Massachusetts.

Key metrics

ETFs linked to THRD

Broad-market and Healthcare sector ETFs an investor holding Third Harmonic Bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how THRD fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Third Harmonic Bio?

Third Harmonic Bio trades under the ticker THRD on NASDAQ.

Which exchange is THRD listed on?

THRD is listed on NASDAQ.

What sector does Third Harmonic Bio operate in?

Third Harmonic Bio is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze THRD in a portfolio?

PortView shows THRD's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.